Spinifex attracts $45M, and new backers on neuropathic pain data
By Nuala Moran
Thursday, April 10, 2014
LONDON Australian biotech Spinifex Pharmaceuticals carried the momentum generated by positive phase II data for its lead chronic pain program forward into a $45 million series C round that has attracted backing from premier U.S. and European investors.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.